Rifabutin Analogs for Treatment of M. abscessus Bacterial Infections
Summary
USPTO published patent application US20260098046A1 for new rifabutin analog compounds and pharmaceutical compositions for treating bacterial infections, with particular focus on non-tuberculous mycobacteria including M. abscessus. The application was filed on September 29, 2023 by a team of nine inventors. This is a published patent application, not a granted patent.
What changed
USPTO published patent application US20260098046A1 disclosing new rifabutin analog compounds and pharmaceutical compositions for treating bacterial infections, particularly those caused by non-tuberculous mycobacteria such as M. abscessus. The application, filed by nine named inventors including Kevin Antraigues and Sergio Lociuro, covers chemical compounds classified under CPC codes including C07D 498/22 and various A61K therapeutic formulations.
Affected parties including pharmaceutical manufacturers, biotechnology researchers, and drug developers should monitor this application's progression through examination. If granted, the patent could restrict generic competition for rifabutin analog formulations targeting M. abscessus infections, creating potential licensing or partnership opportunities for parties seeking to develop or commercialize related antibiotic therapies.
What to do next
- Monitor patent prosecution for grant or rejection
Archived snapshot
Apr 10, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
RIFABUTIN ANALOGS FOR THE TREATMENT OF DISEASE
Application US20260098046A1 Kind: A1 Apr 09, 2026
Inventors
Kevin ANTRAYGUES, Marilyne BOUROTTE, Glenn E. DALE, Olivier DEFERT, Marc GITZINGER, Sergio LOCIURO, Mathieu MAINGOT, Vincent TREBOSC, Nicolas WILLAND
Abstract
The present invention relates to compounds and pharmaceutical compositions comprising the same for the treatment, amelioration and/or prevention of disease. In some embodiments, the disease is a bacterial infection. In some embodiments, the bacterial infection is caused by one or more bacterium belonging to a genus of non-tuberculous Mycobacteria, preferably M. abscessus.
CPC Classifications
C07D 498/22 A61K 31/438 A61K 31/444 A61K 31/4545 A61K 31/496 A61K 31/541 A61K 31/55
Filing Date
2023-09-29
Application No.
19115111
Related changes
Get daily alerts for USPTO Patent Applications - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Organic Chemistry (C07D) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.